Home LiteratureArticle Details
PMID: 10764044 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.

Brain pathology (Zurich, Switzerland) ·Vol. 10 ·No. 2 ·2000-04-00 ·Pages 249-59

Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW

Abstract

Classification of high grade astrocytomas of children into genetic subtypes similar to the adult remains to be defined. Here we report an extensive characterization of 29 high grade pediatric astrocytomas, 7 WHO grade III and 22 WHO grade IV, for genetic alterations frequently observed in high grade adult astrocytomas occurring in either the p53/MDM2/p14ARF or Rb/CDK4/p16INK4a tumor suppressor pathways. In addition, we have assessed the contribution of EGFR overexpression and amplification and LOH for chromosome 10, two genetic alterations commonly associated with the development of de novo adult glioblastoma for their roles in the development of de novo astrocytomas of childhood. Our results suggest two major differences in the genetic pathway(s) leading to the formation of de novo high grade astrocytomas in children compared with those of the adult. Our findings show preferential inactivation of the p53 tumor suppressor pathway in >95% of pediatric astrocytomas versus inactivation of the Rb tumor suppressor pathway in <25% of the same tumors. In addition, de novo high grade pediatric astrocytomas lack amplification of the EGFR gene compared with EGFR amplification in one-third of adult glioblastomas. Since drug treatments and gene therapy strategies exploit specific genetic alterations in tumor cells, our findings have important implications for the future development of treatments for high grade pediatric astrocytomas.

MeSH Terms
Adolescent Adult Carrier Proteins/genetics Central Nervous System Neoplasms/genetics,metabolism,pathology Child Child, Preschool Chromosomes, Human, Pair 10/genetics Chromosomes, Human, Pair 9/genetics Cyclin-Dependent Kinase Inhibitor p16 Diagnosis, Differential ErbB Receptors/genetics,metabolism Female Gene Amplification Gene Deletion Gene Expression Gene Silencing Genes, Tumor Suppressor/genetics Glioblastoma/genetics,metabolism,pathology Humans Male Nuclear Proteins PTEN Phosphohydrolase Phosphoric Monoester Hydrolases/genetics Proto-Oncogene Proteins/genetics,metabolism Proto-Oncogene Proteins c-mdm2 Tumor Suppressor Protein p53/genetics,metabolism Tumor Suppressor Proteins
Chemicals
Carrier Proteins Cyclin-Dependent Kinase Inhibitor p16 Nuclear Proteins Proto-Oncogene Proteins Tumor Suppressor Protein p53 Tumor Suppressor Proteins MDM2 protein, human Proto-Oncogene Proteins c-mdm2 ErbB Receptors Phosphoric Monoester Hydrolases PTEN Phosphohydrolase PTEN protein, human
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Sung T
Department of Pathology, New York University School of Medicine, NY 10016, USA.
Miller D C
Hayes R L
Alonso M
Yee H
Newcomb E W
References (50)
50 references, click to expand
  1. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
    J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 PMID: 9690672
  2. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
    Cancer Res. 1993 Jun 15;53(12):2736-9 PMID: 8504413
  3. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
    Am J Pathol. 1998 Dec;153(6):1749-65 PMID: 9846966
  4. p53 gene mutations in pontine gliomas of juvenile onset.
    Biochem Biophys Res Commun. 1993 Oct 29;196(2):851-7 PMID: 8240361
  5. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    J Neurosurg. 1994 Sep;81(3):427-36 PMID: 8057151
  6. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
    Cancer Res. 1998 Jan 1;58(1):29-33 PMID: 9426052
  7. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
    J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30 PMID: 9600204
  8. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
    Oncogene. 1994 Mar;9(3):949-54 PMID: 8108140
  9. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
    Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 PMID: 8864278
  10. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
    Cancer Res. 1997 Dec 1;57(23):5221-5 PMID: 9393738
  11. Somatic mutations of PTEN in glioblastoma multiforme.
    Cancer Res. 1997 Oct 1;57(19):4183-6 PMID: 9331071
  12. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival.
    J Neurooncol. 1997 Oct;35(1):13-28 PMID: 9266437
  13. p53 gene mutations in pediatric brain tumors.
    Med Pediatr Oncol. 1995 Dec;25(6):431-6 PMID: 7565304
  14. Subsets of glioblastoma multiforme defined by molecular genetic analysis.
    Brain Pathol. 1993 Jan;3(1):19-26 PMID: 8269081
  15. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
    Cell. 1998 Mar 20;92(6):713-23 PMID: 9529248
  16. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
    Brain Pathol. 1998 Oct;8(4):655-67 PMID: 9804374
  17. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
    Cell. 1998 Mar 20;92(6):725-34 PMID: 9529249
  18. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme.
    J Neurosurg. 1992 Aug;77(2):295-301 PMID: 1320666
  19. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Br J Cancer. 1997;75(9):1269-78 PMID: 9155045
  20. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
    J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 PMID: 9210874
  21. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Nature. 1995 Nov 9;378(6553):206-8 PMID: 7477327
  22. PTEN mutations in gliomas and glioneuronal tumors.
    Oncogene. 1998 Apr 30;16(17):2259-64 PMID: 9619835
  23. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Oncogene. 1999 Apr 1;18(13):2241-51 PMID: 10327070
  24. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Cancer Res. 1996 Jan 1;56(1):150-3 PMID: 8548755
  25. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Cancer Res. 1999 Mar 15;59(6):1236-43 PMID: 10096554
  26. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
    Cancer Res. 1994 Nov 15;54(22):5804-7 PMID: 7954404
  27. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.
    Cancer Res. 1997 Apr 15;57(8):1419-24 PMID: 9108438
  28. Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations.
    Cancer Genet Cytogenet. 1998 Apr 15;102(2):93-9 PMID: 9546059
  29. Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4A genes in astrocytomas.
    Diagn Mol Pathol. 1997 Apr;6(2):115-22 PMID: 9098651
  30. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.
    Cancer Res. 1999 Jan 1;59(1):1-7 PMID: 9892174
  31. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme.
    Brain Pathol. 1993 Jul;3(3):229-35 PMID: 8293182
  32. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.
    Acta Neuropathol. 1997 Oct;94(4):303-9 PMID: 9341929
  33. Glioblastoma multiforme in children.
    J Neurosurg. 1976 Apr;44(4):442-8 PMID: 176331
  34. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme.
    Brain Pathol. 1997 Jul;7(3):871-5 PMID: 9217972
  35. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.
    Cancer Res. 1992 Mar 15;52(6):1427-33 PMID: 1347252
  36. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens.
    J Neuropathol Exp Neurol. 1993 Sep;52(5):507-15 PMID: 8103086
  37. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
    J Neuropathol Exp Neurol. 1997 Feb;56(2):180-5 PMID: 9034372
  38. The lack of a role for p53 in astrocytomas in pediatric patients.
    Neurosurgery. 1994 Jun;34(6):967-72; discussion 972-3 PMID: 8084407
  39. The p53-mdm-2 autoregulatory feedback loop.
    Genes Dev. 1993 Jul;7(7A):1126-32 PMID: 8319905
  40. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
    J Neuropathol Exp Neurol. 1999 Feb;58(2):120-8 PMID: 10029095
  41. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
    Cancer Res. 1998 Jul 1;58(13):2825-31 PMID: 9661897
  42. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
    Cancer Res. 1997 Jan 15;57(2):304-9 PMID: 9000573
  43. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours.
    J Pathol. 1997 May;182(1):54-61 PMID: 9227342
  44. Genetic alterations in pediatric high-grade astrocytomas.
    Hum Pathol. 1999 Nov;30(11):1284-90 PMID: 10571506
  45. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
    Nat Genet. 1997 Apr;15(4):356-62 PMID: 9090379
  46. Analysis of glioma cell lines for amplification and overexpression of MDM2.
    Genes Chromosomes Cancer. 1994 Oct;11(2):91-6 PMID: 7529554
  47. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
    Cancer Res. 1992 Feb 1;52(3):674-9 PMID: 1346255
  48. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors.
    Mod Pathol. 1997 Mar;10(3):252-8 PMID: 9071734
  49. Alterations of the TP53 gene in human gliomas.
    Cancer Res. 1994 Mar 1;54(5):1324-30 PMID: 8118823
  50. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
    Cell. 1995 Dec 15;83(6):993-1000 PMID: 8521522
Article Info
Journal
Brain pathology (Zurich, Switzerland)
Abbr.
Brain Pathol
ISSN
1015-6305
Published
2000-04-00
Pages
249-59
Language
English
Region
Switzerland
NLM ID
9216781
PMCID
PMC8098142
Subset
IM
Grants
NCI NIH HHS · CA 16087 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com